The groundbreaking success of the copyright undeniably revolutionized the medication landscape, but placing funds in companies strongly reliant on unbranded versions presents a uncertain picture. Although early earnings were substantial, the cessation of patents and the appearance of discounted alternatives have weakened market share. Therefore, a